McKesson Corporation’s Stock Price Plummets to $690.25, Taking a 4.45% Hit in Latest Market Shift

McKesson Corporation (MCK)

690.25 USD -32.12 (-4.45%) Volume: 1.92M

McKesson Corporation’s stock price stands at 690.25 USD, experiencing a decrease of -4.45% this trading session with a trading volume of 1.92M, yet showing a promising year-to-date increase of +21.12%, reflecting the company’s robust performance in the market.

Latest developments on McKesson Corporation

McKesson Corp stock price saw a boost today after the company reported encouraging 2026 profit guidance and surpassed earnings expectations in its fiscal Q4 report. Despite falling short on revenue at $90.8 billion, McKesson’s EPS exceeded estimates at $10.01. The company also projects 11-14% EPS growth for FY26, leading to a 31% return following InvestingPro’s fair value signal. Analyst Jim Cramer praised McKesson as a “middleman money machine” that continues to defy doubts and deliver strong financial performance. With shares on the rise, investors are eagerly anticipating the company’s continued success.

McKesson Corporation on Smartkarma

Analysts at Baptista Research on Smartkarma are bullish on Mckesson Corp, the largest drug distributor in the U.S. One report titled “Is McKesson Wall Street’s Safe Haven? How This Drug Giant Can Thrive In Uncertain Times!” highlights the company’s supply chain resilience, diversified business model, and essential role in healthcare delivery as factors that could insulate it from economic and policy headwinds. Another report, “McKesson Corporation: Growth in Prescription Technology Solutions (RxTS) to Solidify Its Competitive Advantage!”, points out the company’s robust financial performance and strategic advancements, including an 18% revenue increase to $95.3 billion and a 16% growth in adjusted operating profit in the third quarter of fiscal 2025.

In a separate report by Baptista Research, “McKesson Corporation: Will Its Cost Optimization & Operational Efficiencies Help Alter The Playing Field? – Major Drivers”, the second quarter fiscal 2025 results of McKesson Corporation show a strong 21% year-over-year revenue increase to $93.7 billion. The U.S. Pharmaceutical segment played a significant role in driving this growth with a 23% revenue boost, attributed to the onboarding of a new strategic partner and expanded specialty product distribution. These reports collectively paint a positive picture of Mckesson Corp‘s financial standing and future prospects in the healthcare industry.

A look at McKesson Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Mckesson Corp has a positive long-term outlook. With high scores in Growth and Momentum, the company is positioned for strong future performance. This indicates that Mckesson Corp is expected to experience significant growth and maintain positive momentum in the market.

Although Mckesson Corp may not score as well in terms of Value, the company still demonstrates resilience and offers a moderate dividend. Overall, Mckesson Corp‘s diverse business model and focus on healthcare products and services position it well for continued success in the industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma